Applied Genetic Technologies Inc. (NASDAQ: AGTC) stock plunged by 3.7% at last close whereas the AGTC stock price gains by 2.56% in the pre-market trading session. AGTC is a clinical-stage biotechnology firm focused on discovering genetic treatments for patients suffering from uncommon and debilitating ophthalmic, otologic, and CNS disorders.
AGTC stock’ Important Event
The Fourteenth International Symposium on Retinal Degeneration will feature a presentation of Applied Genetic Technologies Corporation’s current clinical studies in achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRPc) (RD2021).
- On September 29, 2021, Rachel Huckfeldt, MD, PhD, Assistant Professor of Ophthalmology at Harvard Medical School, will give a presentation titled Twelve-Month Findings from Two Phase 1/2 Clinical Trials of Subretinal Gene Therapy for Achromatopsia in Adults and Low-Dose Pediatrics.
- However the same day, Paul Yang, MD, PhD, Assistant Professor of Ophthalmology at Oregon Health & Science University in Portland, will reveal Twelve-Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1/2 Clinical trial of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa.
AGTC intends to move its ACHM programme to the next level of clinical testing, submitting an End-of-Phase 2 (EOP2) briefing package to the US Food and Drug Administration, creating pivotal readiness testing assays, and arranging clinical trial material manufacturing.
Sue Washer, President and CEO of AGTC stated,
They hope that their scientists will be able to share their findings and analyses with members of the eye health community. They think the findings support the broad use of their AAV technology platform, such as the best-in-class potential of their XLRP treatment candidate and the need for more clinical research into their therapy to cure ACHM.
Dr. Huckfeldt commented,
ACHM is a hereditary disorder resulting from mutations in one of the many genes, along with the CNGB3 or CNGA3 genes that results in non-functioning “cone” photoreceptors that are necessary for accurate vision. It is associated with poor visual acuity, severe light sensitivity, daytime loss of vision, and partial or full loss of colour discrimination. These findings are quite encouraging, and he is excited to share them with my retinal colleagues.
